Back to top
more

G1 THERAPEUTICS (GTHX)

(Delayed Data from NSDQ)

$21.61 USD

21.61
229,042

+0.72 (3.45%)

Updated May 3, 2019 04:00 PM ET

After-Market: $21.60 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Brokerage Reports

[GTHX]

Reports for Purchase

Showing records 301 - 320 ( 361 total )

Industry: Medical - Biomedical and Genetics

Record: 301

06/14/2019

Industry Report

Pages: 11

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 302

06/06/2019

Industry Report

Pages: 38

Biotechnology - ASCO Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 303

05/31/2019

Industry Report

Pages: 14

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 304

05/17/2019

Daily Note

Pages: 15

Biotechnology- ASCO Abstract Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 305

05/14/2019

Company Report

Pages: 7

Not so Fas(lodex)! Here Comes G1T48

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 306

05/10/2019

Company Report

Pages: 8

1Q19 Results; Trilaciclib Filings Expected 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 307

04/30/2019

Daily Note

Pages: 4

GTHX, FDA Seeing 20/20 for 2020 Trila NDA

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 308

04/30/2019

Daily Note

Pages: 3

Positive Trilaciclib End-of-Phase 2 Meeting With FDA; NDA Filing Anticipated in 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 309

04/05/2019

Industry Report

Pages: 23

Biotechnology - AACR Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 310

03/29/2019

Industry Report

Pages: 10

HEALTHCARE: The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 311

03/07/2019

Company Report

Pages: 8

Highlights From Investor Conference: G1 Provides Program Updates; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 312

03/07/2019

Daily Note

Pages: 7

G1 Analyst Investor Day: Commercial - Regulatory Strategies Emerging for Trila

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 313

03/01/2019

Company Report

Pages: 7

Whither Trila and Regulators?

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 314

03/01/2019

Daily Note

Pages: 15

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 315

03/01/2019

Company Report

Pages: 8

G1 Therapeutics Reports 4Q18 Results and Trilaciclib Progress; PT to $72 from $75

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 316

02/08/2019

Daily Note

Pages: 8

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 317

01/18/2019

Industry Report

Pages: 9

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 318

01/14/2019

Industry Report

Pages: 9

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 319

12/20/2018

Company Report

Pages: 7

G1 Therapeutics Again Reports Positive Topline Phase 2 Trilaciclib Myelopreservation Data in SCLC

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 320

12/20/2018

Daily Note

Pages: 5

4/4: G1 Looking to Dance With Regulators in H1:19

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party